
|Videos|December 12, 2021
How Asciminib Has Impacted the CML Treatment Landscape
Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses how asciminib has impacted the treatment landscape for chronic myeloid leukemia.
Advertisement
Pharmacy Times interviewed Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, on her presentation at the 63rd American Society of Hematology Annual Meeting & Exposition on new longer-term efficacy and safety data from the pivotal phase 3 ASCEMBL study for FDA-approved asciminib.
During the interview, Mendila discussed how the recent FDA approval of asciminib for chronic myeloid leukemia (CML) has impacted the CML treatment landscape.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
3
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
4
Could VER-01 Redefine the Role of Cannabis in Chronic Pain Care?
5





































































































